These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
þ
|
No fee required.
|
|
o
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|
1)
|
Title of each class of securities to which transaction applies:
|
|
2)
|
Aggregate number of securities to which transaction applies:
|
|
3)
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
|
|
4)
|
Proposed maximum aggregate value of transaction:
|
|
5)
|
Total fee paid:
|
|
o
|
Fee paid previously with preliminary materials.
|
|
o
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
|
|
1)
|
Amount Previously Paid:
|
|
2)
|
Form, Schedule or Registration Statement No.:
|
|
3)
|
Filing Party:
|
|
4)
|
Date Filed:
|
|
1.
|
To elect three Class II directors, each to serve three-year terms through the third annual meeting of stockholders following this meeting and until a successor has been elected and qualified or until earlier resignation or removal.
|
|
2.
|
To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016.
|
|
3.
|
To approve an amendment to Trupanion’s Restated Certificate of Incorporation to decrease the number of authorized shares of common stock from 200,000,000 to 100,000,000.
|
|
|
Page
|
|
•
|
vote in person
— we will provide a ballot to stockholders who attend the meeting and wish to vote in person;
|
|
•
|
vote through the Internet
— in order to do so, please follow the instructions shown on your Notice of Internet Availability or proxy card;
|
|
•
|
vote by telephone
— in order to do so, please follow the instructions shown on your Notice of Internet Availability or proxy card; or
|
|
•
|
vote by mail
— if you request or receive a paper proxy card and voting instructions by mail, simply complete, sign and date the proxy card and return it as soon as possible before the meeting in the envelope provided.
|
|
•
|
delivering to the Corporate Secretary a written notice stating that the proxy is revoked;
|
|
•
|
signing and delivering a proxy bearing a later date;
|
|
•
|
voting again through the Internet; or
|
|
•
|
attending and voting at the meeting (although attendance at the meeting will not, by itself, revoke a proxy).
|
|
•
|
view our proxy materials for the meeting through the Internet;
|
|
•
|
instruct us to mail paper copies of our future proxy materials to you; and
|
|
•
|
instruct us to send our future proxy materials to you electronically by email.
|
|
•
|
our accounting and financial reporting processes, including our financial statement audits and the integrity of our financial statements;
|
|
•
|
our compliance with legal and regulatory requirements;
|
|
•
|
the qualifications, independence and performance of our independent auditors; and
|
|
•
|
the preparation of the audit committee report to be included in our annual proxy statement.
|
|
•
|
evaluating, recommending, approving and reviewing executive officer and director compensation arrangements, plans, policies and programs;
|
|
•
|
administering our cash-based and equity-based compensation plans; and
|
|
•
|
making recommendations to our Board of Directors regarding any other Board of Director responsibilities relating to executive compensation.
|
|
•
|
identifying, considering and recommending candidates for membership on our Board of Directors;
|
|
•
|
developing and recommending our corporate governance guidelines and policies;
|
|
•
|
overseeing the process of evaluating the performance of our Board of Directors; and
|
|
•
|
advising our Board of Directors on other corporate governance matters.
|
|
•
|
Code of Conduct and Ethics that sets forth our ethical principles and applies to all of our directors, officers and employees, including our Chief Executive Officer and Chief Financial Officer;
|
|
•
|
Corporate Governance Guidelines that set forth our corporate governance principles; and
|
|
•
|
charters for our audit, compensation and nominating and corporate governance committees.
|
|
Name of Director/Nominee
|
|
Age
|
|
Principal Occupation
|
|
Director Since
|
|
Chad Cohen
(1)
|
|
41
|
|
Chief Financial Officer, Adaptive Biotechnologies Corporation
|
|
December 2015
|
|
Michael Doak
(1) (2)
|
|
40
|
|
President, RenaissanceRe Ventures U.S. LLC; and
Senior Vice President, RenaissanceRe Ventures Ltd.
|
|
February 2014
|
|
Darryl Rawlings
|
|
46
|
|
President and Chief Executive Officer, Trupanion, Inc.
|
|
January 2000
|
|
(1)
|
Member of the audit committee
|
|
(2)
|
Member of the nominating and corporate governance committee
|
|
Name of Director
|
|
Age
|
|
Principal Occupation
|
|
Director Since
|
|
Class I Directors:
|
|
|
|
|
|
|
|
Robin Ferracone
(1) (2)
|
|
62
|
|
Founder and Chief Executive Officer, Farient Advisors LLC
|
|
December 2014
|
|
H. Hays Lindsley
(1) (3)
|
|
57
|
|
Member of Investment Team, Petrus Asset Management Company
|
|
February 2013
|
|
Glenn Novotny
(3)
|
|
69
|
|
Founder and Owner, Glennhawk Vineyards and Emerald Pet Products
|
|
February 2013
|
|
Class III Directors:
|
|
|
|
|
|
|
|
Dan Levitan
(1) (2)
|
|
58
|
|
Managing Member, Maveron LLC
|
|
April 2007
|
|
Murray Low
(1) (2)
|
|
63
|
|
Professor, Columbia Business School
|
|
April 2006
|
|
Howard Rubin
|
|
63
|
|
Consultant, Trupanion, Inc.
|
|
March 2010
|
|
(1)
|
Member of the compensation committee
|
|
(2)
|
Member of the nominating and corporate governance committee
|
|
(3)
|
Member of the audit committee
|
|
Name
(1)
|
Option Awards ($)
(2)
|
|
|
All Other Compensation ($)
|
|
|
Total
|
|||||||
|
Dr. Peter R. Beaumont
(3)
|
$
|
50,000
|
|
|
|
$
|
108,000
|
|
|
|
$
|
158,000
|
|
|
|
Robin Ferracone
|
$
|
80,000
(4)
|
|
|
|
$
|
—
|
|
|
|
$
|
80,000
|
|
|
|
Howard Rubin
|
$
|
—
|
|
|
|
$
|
304,500
(5)
|
|
|
|
$
|
304,500
|
|
|
|
(1)
|
Chad Cohen, Michael Doak, Dan Levitan, H. Hays Lindsley, Murray Low and Glenn Novotny also served as non-employee members of our Board of Directors in 2015. None of these directors were paid any compensation during 2015, nor did they hold any outstanding options to purchase shares of our common stock as of December 31, 2015, except for Dr. Low, who held options to purchase 8,750 shares of common stock at an exercise price of $4.05 per share, and Mr. Novotny, who held options to purchase 50,000 shares of common stock at an exercise price of $1.04 per share.
|
|
(2)
|
The amounts reported in this column represent the aggregate grant date fair value of the stock options granted to our directors during the year ended December 31, 2015, as computed in accordance with Accounting Standards Codification Topic 718. The assumptions used in calculating the aggregate grant date fair value of the stock options reported in this column are set forth in Note 11 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2015. The amounts reported in this column reflect the accounting cost for these stock options, and do not correspond to the actual economic value that may be received by our directors from the stock options.
|
|
(3)
|
Dr. Beaumont resigned as a director in December 2015. Amounts represent compensation paid to Dr. Beaumont for consulting services, which compensation consisted of $108,000 in cash and stock options to purchase 15,441 shares of common stock at an exercise price of $7.44 per share. As of December 31, 2015, Dr. Beaumont held outstanding options to purchase 56,303 shares of common stock at an exercise price of $1.04 per share and 15,441 shares of common stock at an exercise price of $7.44 per share.
|
|
(4)
|
In February 2015, in connection with her December 2014 appointment to the Board of Directors, Ms. Ferracone was granted an option to purchase 23,360 shares of common stock at an exercise of $7.73 per share. All of such stock options remained outstanding as of December 31, 2015.
|
|
(5)
|
Amount represents compensation paid to Mr. Rubin for certain services unrelated to his service as a director, including attending animal health industry events on our behalf.
|
|
|
|
Fiscal Year 2015
|
|
|
Fiscal Year 2014
|
||||
|
Audit fees
(1)
|
$
|
431,500
|
|
|
|
$
|
1,373,000
|
|
|
|
Audit related fees
(2)
|
|
—
|
|
|
|
|
—
|
|
|
|
Tax fees
(3)
|
|
25,500
|
|
|
|
|
—
|
|
|
|
All other fees
(4)
|
|
1,995
|
|
|
|
|
2,000
|
|
|
|
Total fees
|
$
|
458,995
|
|
|
|
$
|
1,375,000
|
|
|
|
(1)
|
Audit fees consist of fees for professional services provided in connection with the audit of our annual consolidated financial statements, the review of our quarterly consolidated financial statements, and audit services that are normally provided by independent registered public accounting firm in connection with statutory and regulatory filings or engagements for those fiscal years, such as statutory audits. The audit fees also include fees for professional services provided in connection with our initial public offering, incurred during the fiscal year ended December 31, 2014, including comfort letters, consents and review of documents filed with the SEC.
|
|
(2)
|
Audit-related fees
include fees billed for assurance and related services reasonably related to the performance of the audit.
|
|
(3)
|
Tax fees
include fees for tax compliance and advice.
|
|
(4)
|
All other fees consist of fees for access to online accounting and tax research software.
|
|
•
|
each stockholder known by us to be the beneficial owner of more than 5% of our common stock;
|
|
•
|
each of our directors or director nominees;
|
|
•
|
each of our named executive officers; and
|
|
•
|
all of our directors and executive officers as a group.
|
|
Name of Beneficial Owner
|
|
Number of Shares
Beneficially Owned |
|
Percentage
|
|
|
|
|
|
|
|
|
|
5% or greater stockholders:
|
|
|
|
|
|
|
Entities affiliated with Maveron
(1)
|
|
6,553,586
|
|
|
22.9%
|
|
Entities affiliated with Highland Consumer Fund
(2)
|
|
3,096,427
|
|
|
10.8%
|
|
RenaissanceRe Ventures Ltd.
(3)
|
|
2,755,000
|
|
|
9.6%
|
|
Capital World Investors
(4)
|
|
2,257,500
|
|
|
7.9%
|
|
Wasatch Advisors, Inc.
(5)
|
|
1,941,984
|
|
|
6.8%
|
|
Directors and Named Executive Officers:
|
|
|
|
|
|
|
Darryl Rawlings
(6)
|
|
2,448,366
|
|
|
8.3%
|
|
Michael Banks
(7)
|
|
274,923
|
|
|
*
|
|
Timothy Graff
(8)
|
|
76,801
|
|
|
*
|
|
Chad Cohen
(9)
|
|
5,120
|
|
|
*
|
|
Michael Doak
(10)
|
|
5,120
|
|
|
*
|
|
Robin Ferracone
(11)
|
|
57,269
|
|
|
*
|
|
Dan Levitan
(1) (12)
|
|
6,558,706
|
|
|
23.0%
|
|
H. Hays Lindsley
(13)
|
|
71,790
|
|
|
*
|
|
Murray Low
(14)
|
|
260,683
|
|
|
*
|
|
Glenn Novotny
(15)
|
|
128,976
|
|
|
*
|
|
Howard Rubin
(16)
|
|
790,639
|
|
|
2.7%
|
|
|
|
|
|
|
|
|
All officers and directors as a group (13 persons)
(17)
|
|
10,790,758
|
|
|
37.4%
|
|
(1)
|
Based solely on the Schedule 13G filed by Maveron Equity Partners III, L.P. (Maveron Equity) on February 12, 2016. Consists of (i) 5,556,046 shares held by Maveron Equity, (ii) 235,731 shares held by Maveron III Entrepreneurs’ Fund, L.P. (Maveron Entrepreneurs) and (iii) 761,809 shares held by MEP Associates III, L.P. (together with Maveron Equity and Maveron Entrepreneurs, the Maveron Entities). Maveron General Partner III LLC (Maveron LLC) is the general partner of each of the Maveron Entities. Dan Levitan, a member of our Board of Directors, Clayton Lewis, Peter McCormick and Jason Stoffer are the managing members of Maveron LLC and, as such, share voting and dispositive power over the shares held by the Maveron Entities. The principal business address of each of the Maveron Entities is 411 First Avenue South, Suite 600, Seattle, Washington 98104.
|
|
(2)
|
Based on the Schedule 13G filed by Highland Consumer GP GP LLC (HC LLC) on February 16, 2016. Consists of (i) 2,438,064 shares and 48,176 shares underlying warrants to purchase common stock that are exercisable within 60 days of April 1, 2016 are held by Highland Consumer Fund I Limited Partnership (Highland Consumer I), (ii) 520,175 shares and 10,278 shares underlying warrants to purchase common stock that are exercisable within 60 days of April 1, 2016 are held by Highland Consumer Fund 1-B Limited Partnership (Highland Consumer 1B) and (iii) 78,189 shares and 1,545 shares underlying warrants to purchase common stock that are exercisable within 60 days of April 1, 2016 are held by Highland Consumer Entrepreneurs’ Fund I, Limited Partnership (together with Highland Consumer I and Highland Consumer 1B, the Highland Entities). Highland Consumer GP Limited Partnership (HC LP) is the general partner of each of the Highland Entities. HC LLC is the general partner of HC LP.
Peter Cornetta, Daniel Nova and Thomas Stemberg are the managers of HC LLC. Each of HC LP and HC LLC, as the general partner of the general partner of the Highland Entities, respectively, is deemed to have beneficial ownership of the shares held by the Highland Entities. Voting and investment decisions of HC LLC are made by the managers of HC LLC. The principal business address for the Highland Consumer Entities is One Broadway, 16th Floor, Cambridge, Massachusetts 02142.
|
|
(3)
|
Based solely on the Schedule 13G filed by RenaissanceRe Ventures Ltd. (Ventures) on February 5, 2016. Consists of 2,755,000 shares. Ventures is a wholly owned subsidiary of Renaissance Other Investments Holdings II Ltd. (Holdings), which in turn is a wholly owned subsidiary of RenaissanceRe Holdings Ltd. (RenaissanceRe). By virtue of these relationships, RenaissanceRe and Holdings may be deemed to have voting and dispositive power over the shares held by Ventures. The principal business address of RenaissanceRe is Renaissance House, 12 Crow Lane, Pembroke HM19, Bermuda.
|
|
(4)
|
Based solely on the Schedule 13G filed by Capital World Investors on February 16, 2016. Consists of 2,257,500 shares over which Capital World Investors has sole voting and dispositive power. Capital World Investors is a division of Capital Research and Management Company. The principal business address of Capital World Investors is 333 South Hope Street, Los Angeles, California 90071.
|
|
(5)
|
Based solely on the Schedule 13G filed by Wasatch Advisors, Inc. on February 16, 2016. Consists of 1,941,984 shares over which Wasatch Advisors, Inc. has sole voting and dispositive power. The principal business address of Wasatch Advisors, Inc. is 505 Wakara Way, Salt Lake City, Utah 84108.
|
|
(6)
|
Consists of (i) 1,594,095 shares held by Mr. Rawlings, of which 467,508 are shares of unvested restricted stock subject to our right of repurchase and (ii) 854,271 shares underlying options to purchase common stock that are exercisable within 60 days of April 1, 2016. Mr. Rawlings holdings exclude 120,481 shares held by Rawlings GST Trust dated March 1, 2012, of which Murray Low, a member of our Board of Directors, is the trustee and the Rawlings GST Exempt Trust FBO and Rawlings GST Non-Exempt Trust FBO are the beneficiaries, of which Mr. Rawlings’ children are beneficiaries.
|
|
(7)
|
Consists of (i) 6,175 shares held by Mr. Banks and (ii) 268,748 shares underlying options to purchase common stock that are exercisable within 60 days of April 1, 2016.
|
|
(8)
|
Consists of (i) 33,053 shares held by Mr. Graff and (ii) 43,748 shares underlying options to purchase common stock that are exercisable within 60 days of April 1, 2016.
|
|
(9)
|
Consists of 5,120 shares underlying options to purchase common stock that are exercisable within 60 days of April 1, 2016 held by Mr. Cohen.
|
|
(10)
|
Consists of 5,120 shares underlying options to purchase common stock that are exercisable within 60 days of April 1, 2016 held by Mr. Doak.
|
|
(11)
|
Consists of (i) 28,106 shares held by Robin A. Ferracone TTEE of the Robin A. Ferracone Living Trust dtd 6/3/2002 and (ii) 29,163 shares underlying options to purchase common stock that are exercisable within 60 days of April 1, 2016 held by Ms. Ferracone.
|
|
(12)
|
Consists of 5,120 shares underlying options to purchase common stock that are exercisable within 60 days of April 1, 2016 held by Mr. Levitan.
|
|
(13)
|
Consists of (i) 66,670 shares held by Lindsley Partners, L.P. (Lindsley Partners) and (ii) 5,120 shares underlying options to purchase common stock that are exercisable within 60 days of April 1, 2016 held by Mr. Lindsley. The HHL09 Trust is the sole member of Zoida LLC, which is the general partner of Lindsley Partners. H. Hays Lindsley, a member of our Board of Directors, is the sole trustee of the HHL09 Trust and, as such, holds sole voting and investment power over the shares.
|
|
(14)
|
Consists of (i) 178,630 shares and 14,553 shares underlying options to purchase common stock that are exercisable within 60 days of April 1, 2016 held by Mr. Low and (ii) 67,500 shares held by Murray R. Low ROTH IRA #90GK49015.
|
|
(15)
|
Consists of (i) 5,000 shares and 56,144 shares underlying options to purchase common stock that are exercisable within 60 days of April 1, 2016 held by Mr. Novotny, (ii) 3,004 shares held by Glenn and Linda Novotny 1996 Living Trust, of which Mr. and Mrs. Novotny are beneficiaries and (iii) 64,828 shares held by Linda K. Novotny Irrevocable Trust dated December 27, 2012, of which Scott Kerr is trustee and Christina Kerr, Teresa Novotny-Micheal, Angela Ovalle and Glenn Novotny are beneficiaries.
|
|
(16)
|
Consists of 790,639 shares underlying options to purchase common stock that are exercisable within 60 days of April 1, 2016 held by Mr. Rubin.
|
|
(17)
|
Consists of (i) 8,601,347 shares held by our directors and executive officers as a group and (ii) 2,189,411 shares underlying options to purchase common stock that are exercisable within 60 days of April 1, 2016 held by our directors and executive officers as a group.
|
|
NAME
|
|
AGE
|
|
POSITION
|
|
Executive Officers
|
||||
|
Darryl Rawlings
|
|
47
|
|
Chief Executive Officer, President and Director
|
|
Michael Banks
|
|
56
|
|
Chief Financial Officer
|
|
Tim Graff
|
|
54
|
|
President of American Pet Insurance Company
|
|
Ian Moffat
|
|
40
|
|
Chief Operating Officer
|
|
Margaret Tooth
|
|
37
|
|
Chief Marketing Officer
|
|
Name and principal position
|
Year
|
Salary
|
Option Awards
(1)
|
Stock Awards
(1)
|
Non-equity incentive plan compensation
|
Total
|
|
|
|
($)
|
($)
|
($)
|
($)
|
($)
|
|
|
|
|
|
|
|
|
|
Darryl Rawlings
|
2015
|
300,000
|
—
|
—
|
252,825
|
552,825
|
|
Chief Executive Officer
|
2014
|
300,000
|
—
|
—
|
182,550
|
482,550
|
|
|
|
|
|
|
|
|
|
Michael Banks
|
2015
|
275,000
|
90,048
|
—
|
112,212
|
477,260
|
|
Chief Financial Officer
|
2014
|
275,000
|
—
|
—
|
84,627
|
359,627
|
|
|
|
|
|
|
|
|
|
Timothy Graff
|
2015
|
240,000
|
112,560
|
—
|
66,516
|
419,076
|
|
President of American Pet Insurance Company
|
2014
|
72,355
(2)
|
556,000
|
17,315
(3)
|
—
|
645,670
|
|
(1)
|
The amounts reported in this column represent the aggregate grant date fair value of the stock options and restricted stock granted to our named executive officers during the years ended December 31, 2015 and 2014, as computed in accordance with Accounting Standards Codification Topic 718. The assumptions used in calculating the aggregate grant date fair value of the stock options and restricted stock reported in this column are set forth in Note 11 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2015. The amounts reported in this column reflect the accounting cost for these stock options and restricted stock, and do not correspond to the actual economic value that may be received by our named executive officers from the stock options and restricted stock.
|
|
(2)
|
Mr. Graff's full-time employment commenced on August 1, 2014.
|
|
(3)
|
Mr. Graff was granted 2,385 shares of fully-vested restricted stock under the 2014 Plan in lieu of a cash bonus for 2014.
|
|
NAME
|
|
GRANT DATE
(1)
|
|
NUMBER OF
SECURITIES UNDERLYING UNEXERCISED OPTIONS EXERCISABLE (#) |
|
NUMBER OF
SECURITIES UNDERLYING UNEXERCISED OPTIONS UNEXERCISABLE (#) |
|
OPTION
EXERCISE PRICE ($) |
|
OPTION
EXPIRATION DATE |
|
NUMBER OF
SHARES OR UNITS OF STOCK THAT HAVE NOT VESTED (#) |
|
MARKET
VALUE OF SHARES OR UNITS OF STOCK THAT HAVE NOT VESTED ($) (2) |
||||||||
|
Darryl Rawlings
|
|
12/4/2008
|
(3)
|
544,592
|
|
|
—
|
|
|
$
|
0.90
|
|
|
12/4/2018
|
|
|
—
|
|
|
—
|
|
|
|
|
9/23/2011
|
(4)
|
309,679
|
|
|
—
|
|
|
$
|
1.04
|
|
|
9/23/2021
|
|
|
—
|
|
|
—
|
|
||
|
|
|
8/2/2013
|
(5)
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
467,508
|
|
|
$
|
4,562,878
|
|
|
|
Michael Banks
|
|
6/21/2012
|
(6)
|
175,000
|
|
|
25,000
|
|
|
$
|
4.05
|
|
|
6/21/2022
|
|
|
—
|
|
|
—
|
|
|
|
|
8/2/2013
|
(7)
|
62,500
|
|
|
37,500
|
|
|
$
|
4.77
|
|
|
8/2/2023
|
|
|
—
|
|
|
—
|
|
||
|
|
|
7/24/2015
|
(8)
|
—
|
|
|
19,200
|
|
|
$
|
7.78
|
|
|
7/24/2025
|
|
|
—
|
|
|
—
|
|
|
|
Timothy Graff
|
|
8/1/2014
|
(9)
|
33,333
|
|
|
66,667
|
|
|
$
|
9.90
|
|
|
8/1/2024
|
|
|
—
|
|
|
—
|
|
|
|
|
7/24/2015
|
(10)
|
—
|
|
|
24,000
|
|
|
$
|
7.78
|
|
|
7/24/2025
|
|
|
—
|
|
|
—
|
|
||
|
(1)
|
All of the outstanding equity awards were granted under our 2007 Equity Compensation Plan except for the award granted to Mr. Graff on August 1, 2014 and the awards granted in 2015, which were granted under our 2014 Equity Incentive Plan.
|
|
(2)
|
Calculated based on the closing stock price reported on the New York Stock Exchange on December 31, 2015 of $9.76 per share.
|
|
(3)
|
Twenty-five percent of the shares underlying this option vested on April 25, 2008 and approximately 2% vested monthly thereafter.
|
|
(4)
|
Twenty-five percent of the shares underlying this option vested on September 23, 2012 and approximately 2% vested monthly thereafter.
|
|
(5)
|
Of the 701,262 restricted shares, 116,877 vested on August 2, 2014 and approximately 17% vests on each annual anniversary of that date thereafter.
|
|
(6)
|
Twenty-five percent of the shares underlying this option vested on June 13, 2013 and approximately 2% vests monthly thereafter.
|
|
(7)
|
Twenty-five percent of the shares underlying this option vested on June 28, 2014 and approximately 2% vests monthly thereafter.
|
|
(8)
|
Twenty-five percent of the shares underlying this option vests on July 24, 2016 and approximately 2% vests monthly thereafter.
|
|
(9)
|
Twenty-five percent of the shares underlying this option vested on August 1, 2015 and approximately 2% vests monthly thereafter.
|
|
(10)
|
Twenty-five percent of the shares underlying this option vests on July 24, 2016 and approximately 2% vests monthly thereafter.
|
|
•
|
shares subject to options or stock appreciation rights (SARs) granted under our 2014 Plan that ceased to be subject to the option or SAR for any reason other than exercise of the option or SAR;
|
|
•
|
shares subject to awards granted under our 2014 Plan that were subsequently forfeited or repurchased by us at the original issue price;
|
|
•
|
shares subject to awards granted under our 2014 Plan that otherwise terminated without shares being issued;
|
|
•
|
shares surrendered, canceled, or exchanged for cash or the same type of award or a different award (or combination thereof);
|
|
•
|
shares reserved but not issued or subject to outstanding awards under our 2007 Plan on July 17, 2014;
|
|
•
|
shares issuable upon the exercise of options or subject to other awards under our 2007 Plan prior to July 17, 2014 that ceased to be subject to such options or other awards by forfeiture or otherwise after July 17, 2014;
|
|
•
|
shares issued under our 2007 Plan that were forfeited or repurchased by us after July 17, 2014; and
|
|
•
|
shares subject to awards under our 2007 Plan that were used to pay the exercise price of an option or withheld to satisfy the tax withholding obligations related to any award.
|
|
Plan category |
|
Number of securities to be issued upon exercise
of outstanding options, warrants and rights(#)
|
|
Weighted-average exercise price of outstanding options,
warrants and rights($)
|
|
Number of securities remaining available for future issuance under equity compensation
plans (#)
|
|||
|
Equity compensation plans approved by security holders
(1)
|
|
5,746,824
|
|
|
3.71
(2)
|
|
|
5,353,070
(3)
|
|
|
Equity compensation plans not approved by security holders
|
|
—
|
|
|
—
|
|
|
—
|
|
|
Total
|
|
5,746,824
|
|
|
—
|
|
|
5,353,070
|
|
|
(1)
|
Excludes purchase rights accruing under our 2014 ESPP and includes 467,508 shares of restricted stock and 4,876 shares of restricted stock units.
|
|
(2)
|
The weighted average exercise price relates solely to outstanding stock option shares since shares of restricted stock and restricted stock units have no exercise price.
|
|
(3)
|
Includes 2,284,519 shares of common stock that remain available for purchase under the 2014 ESPP and 3,068,551 shares of common stock that remain available for purchase under our 2014 Plan. Additionally, our 2014 Plan provides for automatic increases in the number of shares available for issuance under it on January 1 of each four calendar years during the term of the 2014 Plan by the lesser of 4% of the number of shares of common stock issued and outstanding on each December 31 immediately prior to the date of increase or the number determined by our Board of Directors. Similarly, on January 1 of each calendar year, the aggregate number of shares of our common stock reserved for issuance under our 2014 ESPP increases automatically by the number of shares equal to the lesser of 1% of the total number of outstanding shares of our common stock on the immediately preceding December 31 or the number determined by our Board of Directors and may never exceed 20,000,000 shares.
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|